SELLAS Life Sciences Group, Inc. - ROE
SLS
Price:
$10.1
Market Cap:
$1.88B
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet...[Read more]
Industry
Biotechnology
IPO Date
2008-03-12
Stock Exchange
NASDAQ
Ticker
SLS
PE Ratio
[-43.91]
ROE
[-47.12%]
Current Ratio
[17.22]
Dividend Yield
[0%]
Enterprise Value
[1.77B]
Dividend History
The ROE as of July 2026 (TTM) for SELLAS Life Sciences Group, Inc. (SLS) is -47.12%
According to SELLAS Life Sciences Group, Inc.’s latest financial reports and current stock price. The company's current ROE is -47.12%. This represents a change of 220.76% compared to the average of -14.69% of the last 4 quarters.
SELLAS Life Sciences Group, Inc. (SLS) Historical ROE (quarterly & annually)
How has SLS ROE performed in the past?
The mean historical ROE of SELLAS Life Sciences Group, Inc. over the last ten years is -298.30%. The current -47.12% ROE has changed -84.20% with respect to the historical average. Over the past ten years (40 quarters), SLS's ROE was at its highest in in the March 2018 quarter at 606.60%. The ROE was at its lowest in in the March 2022 quarter at -416.00%.
Average
-298.30%
Median
-209.18%
Minimum
-1147.54%
Maximum
468.15%
SELLAS Life Sciences Group, Inc. (SLS) ROE by Quarter and Year
Discovering the peaks and valleys of SELLAS Life Sciences Group, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.30%
Maximum Annual ROE = 468.15%
Minimum Annual Increase = -169.69%
Minimum Annual ROE = -1147.54%
| Year | ROE | Change |
|---|---|---|
| 2025 | -37.90% | -88.38% |
| 2024 | -326.27% | -169.69% |
| 2023 | 468.15% | -154.99% |
| 2022 | -851.39% | 736.91% |
| 2021 | -101.73% | 69.75% |
| 2020 | -59.93% | -81.07% |
| 2019 | -316.63% | -39.98% |
| 2018 | -527.55% | -54.03% |
| 2017 | -1147.54% | 1.30% |
| 2016 | -82.18% | -82.62% |
SELLAS Life Sciences Group, Inc. (SLS) Average ROE
How has SLS ROE performed in the past?
The current ROE of SELLAS Life Sciences Group, Inc. (SLS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
34.66%
5-year avg
-169.83%
10-year avg
-298.30%
SELLAS Life Sciences Group, Inc. (SLS) ROE vs. Peers
How is SLS’s ROE compared to its peers?
SELLAS Life Sciences Group, Inc.’s ROE is less than Neonc Technologies Holdings, Inc. (284.28%), greater than MediWound Ltd. (-67.22%), greater than Genfit S.A. (-596.44%), greater than Protara Therapeutics, Inc. (-38.70%), greater than Invivyd, Inc. (-53.48%), greater than Codexis, Inc. (-68.09%), greater than OmniAb, Inc. (-20.31%), less than Armata Pharmaceuticals, Inc. (162.59%), greater than Prelude Therapeutics Incorporated (-118.24%), greater than C4 Therapeutics, Inc. (-50.68%),
| Company | ROE | Market cap |
|---|---|---|
| 284.28% | $90.76M | |
| -67.22% | $184.34M | |
| -596.44% | $445.68M | |
| -38.70% | $214.14M | |
| -53.48% | $159.97M | |
| -68.09% | $133.62M | |
| -20.31% | $232.23M | |
| 162.59% | $167.77M | |
| -118.24% | $268.15M | |
| -50.68% | $389.20M |
Build a custom stock screener for SELLAS Life Sciences Group, Inc. (SLS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SELLAS Life Sciences Group, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
SELLAS Life Sciences Group, Inc. (SLS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like SELLAS Life Sciences Group, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is SELLAS Life Sciences Group, Inc.'s ROE?
How is the ROE calculated for SELLAS Life Sciences Group, Inc. (SLS)?
What is the highest ROE for SELLAS Life Sciences Group, Inc. (SLS)?
What is the 3-year average ROE for SELLAS Life Sciences Group, Inc. (SLS)?
What is the 5-year average ROE for SELLAS Life Sciences Group, Inc. (SLS)?
How does the current ROE for SELLAS Life Sciences Group, Inc. (SLS) compare to its historical average?